Article Text

other Versions

PDF

Letter
Species-specific and pathotype-specific binding of bacteria to zymogen granule membrane glycoprotein 2 (GP2)
  1. Peter Schierack1,
  2. Stefan Rödiger1,
  3. Rafal Kolenda1,
  4. Rico Hiemann1,
  5. Enrico Berger1,
  6. Krzysztof Grzymajło2,
  7. Alexander Swidsinski3,
  8. Thomas Juretzek4,
  9. Dirk Meissner5,
  10. Karsten Mydlak6,
  11. Dirk Reinhold7,
  12. Lisa K Nolan8,
  13. Dirk Roggenbuck1,9
  1. 1Faculty of Natural Sciences, Brandenburg University of Technology Cottbus—Senftenberg, Senftenberg, Germany
  2. 2University of Environmental and Life Sciences, Wroclaw, Poland
  3. 3Innere Klinik, Gastroenterologie, Charité Humboldt Universität, Berlin, Germany
  4. 4Carl-Thiem-Klinikum, Cottbus, Germany
  5. 5Labor Hameln Hildesheim, Hameln, Germany
  6. 6Gemeinschaftslabor Cottbus, Cottbus, Germany
  7. 7Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
  8. 8Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA
  9. 9GA Generic Assays GmbH, Dahlewitz, Germany
  1. Correspondence to Professor Dirk Roggenbuck, Faculty of Natural Sciences, Brandenburg University of Technology Cottbus—Senftenberg, Großenhainer Str. 57, Senftenberg 01968, Germany; dirk.roggenbuck{at}hs-lausitz.de

Statistics from Altmetric.com

Dear Editor,

With interest we read the paper by Juste et al1 proposing the amount of zymogen-granule membrane glycoprotein 2 (GP2) on the surface of intestinal bacteria as a Crohn's disease (CD) marker. Indeed, a decreased GP2 level was found on microbes in patients with CD as compared to those of healthy controls. GP2 is a homologue to the urinary Tamm–Horsefall protein demonstrating an antimicrobial function by binding type 1-fimbriated uropathogenic Escherichia coli (UPEC). Likewise, GP2 seems to interact with intestinal bacteria as a specific receptor of bacterial type-1 fimbriae (FimH) on intestinal microfold cells that are partaking in immune responses against such microbes.2 GP2 is overexpressed in the inflamed intestine of patients with CD and has an immunomodulating role in innate and acquired immune responses.3 ,4 Interestingly, GP2 was identified as autoantigen of pancreatic antibodies in CD.4 Altogether, these findings indicate two major GP2 sources (pancreatic/intestinal) and support a role for GP2 in the interaction between the immune system and intestinal microbiota.3 Thus, loss of tolerance to GP2 could play a role in CD's pathophysiology supposed to be exacerbated by preceding intestinal infections. In general, the findings by Juste et al1 may be explained by a lower pancreatic GP2 secretion, an impaired GP2 binding to bacteria, or by a higher prevalence of bacteria with poor or no GP2 binding in patients with CD.

We have a longstanding interest in GP2's intestinal function and, therefore, we evaluated GP2 as receptor for intestinal bacterial pathotypes by testing the binding of 284 bacteria in a novel binding assay.5 These bacteria were of 8 E. coli pathotypes, 8 Salmonella serovars, 6 other Enterobacteriaceae genera (Klebsiella, Proteus, Buttiauxella, Pantoea, Raoultella, Serratia), and methicillin-resistant Staphylococcus aureus (MRSA) (figure 1).

Figure 1

Binding of Escherichia coli pathotypes to GP2. Human recombinant GP2 expressed in Sf9 cells were immobilised on 96-well plates with anti-FimH antibodies used as positive, or human serum albumin as negative controls. After incubation of bacterial suspensions for 2 h followed by subsequent washing, bound bacteria were stained with a fluorescent dye and counted with an automated fluorescence interpretation system (Aklides, Medipan, Dahlewitz, Germany). Bound bacteria are represented as bacteria per image (bpi, image=0.61 mm2). UPEC: human uropathogenic E. coli (n=24), HFEC: human intestinal commensal (fecal) E. coli (n=24), ETEC: human enterotoxigenic E. coli (n=24), EPEC: human enteropathogenic E. coli (n=24), SAEC: sepsis-associated human E. coli isolated from sepsis patients (n=24), EAEC: human enteroaggregative E. coli (n=17), AFEC: chicken intestinal commensal (avian fecal) E. coli (n=24), CAEC: Crohn's disease-associated E. coli isolated from patients with Crohn's disease (n=20), Salmonella: Salmonella serovar (n=24), Klebsiella: Klebsiella pneumoniae (n=12), Proteus: Proteus mirabilis (n=12), Buttiauxella (n=6), Pantoea: Pantoea agglomerans (n=5), Raoultella: Raoultella ornithinolytica (n=7), Serratia: Serratia fonticola/liquefaciens (n=6), and methillicin-resistant Staphylococcus aureus: MRSA (n=24). Data are displayed as bpi in box-and-whisker plots with far out values, defined as values that are smaller than the lower quartile minus 3 times the IQR, or larger than the upper quartile plus 3 times the IQR, displayed as solid triangles. Posthoc analysis, p<0.05 for the following comparisons: UPEC: ETEC, EAEC, Salmonella, Buttiauxella, Pantoea, Serratia, MRSA. HFEC: ETEC, EAEC, Salmonella, Proteus, Buttiauxella, Pantoea, Serratia, MRSA. ETEC: UPEC, HFEC, EPEC, SAEC, AFEC, CAEC, Salmonella, Klebsiella, Buttiauxella, Pantoea, MRSA. EPEC: ETEC, EAEC, Salmonella, Proteus, Buttiauxella, Pantoea, Serratia, MRSA. SAEC: ETEC, EAEC, Salmonella, Buttiauxella, Pantoea, Serratia, MRSA. EAEC: UPEC, HFEC, EPEC, SAEC, AFEC, CAEC, Salmonella, Klebsiella, Buttiauxella, Pantoea. AFEC: ETEC, EAEC, Salmonella, Buttiauxella, Pantoea, Serratia, MRSA. CAEC: ETEC, EAEC, Salmonella, Buttiauxella, Pantoea, Serratia, MRSA. Salmonella: UPEC, HFEC, ETEC, EPEC, SAEC, EAEC, AFEC, CAEC, Klebsiella, Proteus, Buttiauxella, Pantoea, Raoultella, Serratia, MRSA. Klebsiella: ETEC, EAEC, Salmonella, Buttiauxella, Pantoea, Serratia, MRSA. Proteus: HFEC, EPEC, Salmonella, Buttiauxella, Pantoea, MRSA. Buttiauxella: UPEC, HFEC, ETEC, EPEC, SAEC, EAEC, AFEC, CAEC, Salmonella, Klebsiella, Proteus, Raoultella. Pantoea: UPEC, HFEC, ETEC, EPEC, SAEC, EAEC, AFEC, CAEC, Salmonella, Klebsiella, Proteus, Raoultella. Raoultella: Salmonella, Buttiauxella, Pantoea, MRSA. Serratia: UPEC, HFEC, EPEC, SAEC, AFEC, CAEC, Salmonella, Klebsiella. MRSA: UPEC, HFEC, ETEC, EPEC, SAEC, AFEC, CAEC, Salmonella, Klebsiella, Proteus, Raoultella.

Binding rates of isolates ranged from 0 to 2117 bacteria per image (bpi), and Salmonella isolates exhibited the significantly highest binding to GP2; whereas, Proteus, Buttiauxella, Pantoea, Raoultella, Serratia and MRSA isolates demonstrated low binding (Kruskal–Wallis test, p<0.000001). E. coli pathotypes and Klebsiella expressed medium binding rates. CD-associated E. coli (CAEC) demonstrated no significantly different binding to GP2 than human commensal (fecal) E. coli (HFEC); sepsis-associated E. coli; UPEC, enteropathogenic E. coli (EPEC) or chicken commensal (avian fecal) E. coli, but a higher binding than enterotoxigenic E. coli and human enteroaggregative E. coli (posthoc analysis, p<0.05, respectively).

Nine out of 10 fimH-negative isolates showed low binding to GP2, and one HFEC isolate a high binding rate (473 bpi). GP2 binding of Salmonella, E. coli and other bacterial groups was mannose-sensitive and not glucose-sensitive as shown by inhibition experiments proving a GP2-FimH interaction.

To investigate the interaction between FimH-protein and GP2 at a molecular level, we sequenced fimH genes of 48 E. coli isolates: six isolates of each pathotype including two isolates not binding to GP2, two isolates showing medium and two isolates showing strong binding. Thus, we defined 23 different FimH-amino acid sequences. Though there was no specific FimH-amino acid sequence variation for an E. coli pathotype, FimH sequences seem to correlate with the strength of binding of GP2 to bacteria (figure 2). Additionally, bacterial binding to GP2 correlated significantly with that to anti-FimH antibodies, indicating that FimH-expression levels are associated with GP2 binding (p<0.0001, see online supplementary data).

Figure 2

Correlation between the FimH-amino acid sequences and binding to GP2. E. coli isolates with different binding characteristics to GP2 (n=48) were sequenced and clustered according to the FimH-amino acid sequences. Data on each isolate are: isolate collection number, pathotype, binding to GP2 (low adhesion: <20 bpi; medium adhesion: 50–100 bpi; high adhesion: >300 bpi). UPEC: human uropathogenic E. coli, HFEC: human intestinal (fecal) commensal E. coli, ETEC: human enterotoxigenic E. coli, EPEC: human enteropathogenic E. coli, SAEC: sepsis-associated human E. coli isolated from patients with sepsis, EAEC: human enteroaggregative E. coli, AFEC: chicken intestinal (avian fecal) commensal E. coli, CAEC: Crohn's disease-associated human intestinal E. coli from patients with Crohn's disease.

We conclude that GP2 is an intestinal epithelial receptor interacting with distinct FimH-positive bacteria. This interaction can be modulated by pancreatic GP2 secreted together with zymogens into the intestine. GP2 binding is selective for bacterial species and pathotypes and, thus, may determine immune responses to the intestinal microbiota. CAEC do not differ in their binding from most E. coli isolates supporting the assumptions that other bacteria with low GP2 binding are more abundant in CD, or the GP2 interaction with CAEC is impaired.

References

View Abstract
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Footnotes

  • Contributors DRo, DRe and PS conceived of the study and participated in its design and coordination and helped to draft the manuscript. SR, RK, EB, and KG carried out the experiments. RH developed the pattern recognition algorithms. LKN, DM, KM, AS, and TJ provided the bacterial isolates. All authors read and approved the final manuscript.

  • Competing interests DRo is a shareholder of GA Generic Assays GmbH and Medipan GmbH. The remaining authors declare that they have no competing financial interests.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.